Unmet Needs for Transplant-Eligible NDMM
Panelists discuss how pharmacists can address remaining unmet needs and challenges in optimizing frontline therapy for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM), including areas such as managing complex drug interactions, improving medication adherence, mitigating treatment-related toxicities, streamlining transitions of care, and enhancing patient education and support throughout the treatment journey.
Video content above is prompted by the following:
- What are remaining unmet needs or challenges you see around optimizing frontline therapy for patients with transplant-eligible newly diagnosed multiple myeloma that pharmacists can address?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
September 18th 2025